Savara (SVRA) Long-Term Investments (2012 - 2016)
Savara (SVRA) reported Long-Term Investments of $2.7 million for Q4 2016, down 84.72% year-over-year from $17.9 million in Q1 2016, and down 57.38% on a QoQ basis from $6.4 million in Q3 2016.
Savara (SVRA) has 5 years of Long-Term Investments data on file, last reported at $2.7 million in Q4 2016.
- Quarterly Long-Term Investments fell 84.72% year-over-year to $2.7 million in Q4 2016, while the trailing twelve-month figure through Dec 2016 was $2.7 million (down 84.72% YoY) and the FY2016 annual result came in at $2.7 million, down 84.72% from the prior year.
- Long-Term Investments retreated to $2.7 million in Q4 2016 per SVRA's latest filing, from $6.4 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $22.2 million in Q2 2015 and bottomed at $2.7 million in Q4 2016.
- The 5-year median for Long-Term Investments is $17.9 million (2015), against an average of $16.2 million.
- The widest annual swing landed in 2013, when Long-Term Investments jumped 33.55%; it then sank 84.72% in 2016.
- Tracing SVRA's Long-Term Investments over 5 years: stood at $14.0 million in 2012, then jumped by 33.55% to $18.7 million in 2013, then grew by 14.8% to $21.5 million in 2014, then dropped by 16.54% to $17.9 million in 2015, then slumped by 84.72% to $2.7 million in 2016.
- Per Business Quant, the three latest SVRA Long-Term Investments figures stand at $2.7 million (Q4 2016), $6.4 million (Q3 2016), and $10.6 million (Q2 2016).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 505,194.89 |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 9.79 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 22.17 Mn |
| 10 | Savara | 1.30 Bn | 1.30 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | 2.74 Mn |
| Sep 30, 2016 | 6.43 Mn |
| Jun 30, 2016 | 10.58 Mn |
| Mar 31, 2016 | 13.57 Mn |
| Dec 31, 2015 | 17.93 Mn |
| Sep 30, 2015 | 17.71 Mn |
| Jun 30, 2015 | 22.17 Mn |
| Mar 31, 2015 | 21.95 Mn |
| Dec 31, 2014 | 21.48 Mn |
| Sep 30, 2014 | 17.09 Mn |
| Jun 30, 2014 | 20.07 Mn |
| Mar 31, 2014 | 19.77 Mn |
| Dec 31, 2013 | 18.71 Mn |
| Sep 30, 2013 | 19.13 Mn |
| Dec 31, 2012 | 14.01 Mn |